Literature DB >> 2306735

Transport and metabolism of 9-beta-D-arabinofuranosylguanine in a human T-lymphoblastoid cell line: nitrobenzylthioinosine-sensitive and -insensitive influx.

K L Prus1, D R Averett, T P Zimmerman.   

Abstract

Nitrobenzylthioinosine (NBMPR), dipyridamole, and dilazep, potent inhibitors of nucleoside transport, were found to be ineffective in preventing 9-beta-D-arabinofuranosylguanine (ara-G)-induced inhibition of MOLT 4 and CCRF CEM cell growth, ara-G (2.0 microM) was metabolized to 9-beta-D-arabinofuranosylguanine 5'-triphosphate in MOLT 4 cells, and the levels of this metabolite were not affected by the presence of 5.0 microM NBMPR in the incubation medium. Permeation of the MOLT 4 cell membrane by ara-G occurred primarily by means of the NBMPR-sensitive nucleoside transport system. However, a residual transport component accounting for 10-20% of the total transport activity was demonstrated in the presence of NBMPR. This component was inhibited by adenine and hypoxanthine but not by dilazep, dipyridamole, or other nucleosides. In contrast, inhibitors of nucleoside transport readily reversed the cytotoxic effect of 7-deazaadenosine (tubercidin) in both MOLT 4 and CCRF CEM cells. The levels of tubercidin 5'-triphosphate formed from 2.0 microM tubercidin in MOLT 4 cells were reduced by 80% in the presence of 5.0 microM NBMPR. The influx of tubercidin into MOLT 4 cells was found to occur primarily by means of the NBMPR-sensitive nucleoside transport system. This same system mediated the transport of ara-G into human erythrocytes.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2306735

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity.

Authors:  S M Daluge; S S Good; M B Faletto; W H Miller; M H St Clair; L R Boone; M Tisdale; N R Parry; J E Reardon; R E Dornsife; D R Averett; T A Krenitsky
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

2.  Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action.

Authors:  Karen K Biron; Robert J Harvey; Stanley C Chamberlain; Steven S Good; Albert A Smith; Michelle G Davis; Christine L Talarico; Wayne H Miller; Robert Ferris; Ronna E Dornsife; Sylvia C Stanat; John C Drach; Leroy B Townsend; George W Koszalka
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

3.  Nelarabine in the treatment of refractory T-cell malignancies.

Authors:  Andrew M Roecker; Amy Stockert; David F Kisor
Journal:  Clin Med Insights Oncol       Date:  2010-12-01

4.  Antiviral, metabolic, and pharmacokinetic properties of the isomeric dideoxynucleoside 4(S)-(6-amino-9H-purin-9-yl)tetrahydro-2(S)-furanmethanol.

Authors:  V Nair; M H St Clair; J E Reardon; H C Krasny; R J Hazen; M T Paff; L R Boone; M Tisdale; I Najera; R E Dornsife
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

5.  Transport of the anti-varicella-zoster virus agent 6-methoxypurine arabinoside and its 2'-O-valerate prodrug into human erythrocytes.

Authors:  K L Prus; A C Heidenreich; T P Zimmerman
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

6.  5-Chloro-2',3'-dideoxy-3'-fluorouridine (935U83), a selective anti-human immunodeficiency virus agent with an improved metabolic and toxicological profile.

Authors:  S M Daluge; D J Purifoy; P M Savina; M H St Clair; N R Parry; I K Dev; P Novak; K M Ayers; J E Reardon; G B Roberts
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

Review 7.  Nucleoside salvage and resistance to antimetabolite anticancer agents.

Authors:  M Fox; J M Boyle; A R Kinsella
Journal:  Br J Cancer       Date:  1991-09       Impact factor: 7.640

Review 8.  Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets.

Authors:  Marçal Pastor-Anglada; Sandra Pérez-Torras
Journal:  Front Pharmacol       Date:  2015-02-10       Impact factor: 5.810

9.  Role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.

Authors:  Todd M Cooper
Journal:  Ther Clin Risk Manag       Date:  2007-12       Impact factor: 2.423

Review 10.  New insights into the synergism of nucleoside analogs with radiotherapy.

Authors:  Michael W Lee; William B Parker; Bo Xu
Journal:  Radiat Oncol       Date:  2013-09-26       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.